Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Contrast Enhanced Ultrasound (CEUS) Clear all

Conditions: Liver Cirrhosis
Interventions: Dynamic Contrast-Enhanced Ultrasound Imaging; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: San Diego, California • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Carotid Artery Plaque
Interventions: Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination; Combination Product · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Renal Cell Carcinoma
Interventions: Optison; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cardiac Disease
Interventions: DEFINITY; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Tucson, Arizona • San Diego, California • Wilmington, Delaware + 6 more

Conditions: Hepatic Disease
Interventions: Sulfur Hexafluoride Microspheres; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atherosclerosis, Carotid Artery Plaque
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Interventions: Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound); Drug · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: La Jolla, California • Philadelphia, Pennsylvania

Conditions: Carotid Atherosclerosis
Interventions: Perflutren; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Cancer
Interventions: Contrast-enhanced Ultrasound, Perflutren lipid; Procedure · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Trauma Abdomen
Interventions: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON], contrast-enhanced ultrasound; Drug · Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 0 Years to 17 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Peripheral Artery Disease
Interventions: Contrast ultrasound perfusion imaging of the limb; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hepatocellular Carcinoma
Interventions: Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y); Drug · Device · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Liver Metastases, Colon Cancer
Interventions: Dynamic contrast-enhanced ultrasound imaging, Optical Tracking Device, Electromagnetic Tracking Device, Perflutren; Procedure · Device · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound; Drug · Procedure
Lead sponsor: Versiti Blood Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Conditions: Thyroid Nodules
Interventions: Definity contrast agent; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ovarian Cancer
Interventions: BR55; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Breast Cancer
Interventions: Perflutren Protein-Type A Microspheres Injectable Suspension, Contrast-Enhanced Ultrasound (CEUS), Biopsy + Radioactive Seed Placement, Phone Call; Drug · Device · Procedure + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Local Disease
Interventions: Lumason, Contrast-Enhanced Ultrasound; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Solid Tumor
Interventions: Doppler ultrasound, Long Ensemble Angular-coherence Doppler [LEAD] ultrasound, Contrast-enhanced ultrasound (CEUS); Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Abdominal Trauma
Interventions: Contrast enhanced Ultrasound; Drug
Lead sponsor: David Mooney; Other
Eligibility: 2 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiac Disease
Interventions: DEFINITY®; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 12 more

Conditions: Uterine Fibroid
Interventions: Perfluten; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Definity infusion; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions

New Technologies to Determine Carotid Plaque Vulnerability

Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Risk Assessment of Carotid Plaques Using 3D Contrast-Enhanced Ultrasound

Y-90 Treatment Response Using Transarterial Radioembolization

Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer

CEUS for Blunt Abdominal Trauma in Children

Contrast Ultrasound Assessment of Perfusion Changes After Peripheral Artery Revascularization

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Microvascular Blood Flow in Sickle Cell Anemia

Characterization of Thyroid Nodules Using Contrast Enhanced Ultrasound

Optimal Timing of BR55 CEUS of the Ovaries

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence

Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy

Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma

DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY

Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE

Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy